Thermo Fisher To Acquire GSK API Mfg Site in Ireland for $100 Million

By Patricia Van Arnum - DCAT Editorial Director

May 16, 2019

Thermo Fisher Scientific has agreed to acquire a drug-substance manufacturing site in Cork, Ireland, from GlaxoSmithKline for approximately EUR 90 million ($100.6 million). Thermo says it will expand capacity at the Cork site for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs).

With more than 400 employees, the site produces APIs for treating diseases, such a childhood cancer, depression, and Parkinson's. Thermo Fisher will continue to produce APIs for GSK under a multi-year supply agreement and plans to expand use of the site to develop and produce complex APIs for other customers as well. The site contains 270 cubic meters of reactor capacity, 10 production buildings, an R&D pilot plant, and lab infrastructure to support process development, scale-up and physical characterization of APIs.

The GSK transaction, which is expected to be completed by the end of 2019, is subject to customary closing conditions, including regulatory approvals. Upon completion, the site will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services Segment.

This announcement follows Thermo’s recently completed acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies. Thermo Fisher is also investing $150 million to expand its sterile fill–finish sites in Monza and Ferentino, Italy, and Greenville, North Carolina, and plans to complete the previously announced $50-million expansion of its St. Louis, Missouri biologics facility later this year.

Source: Thermo Fisher Scientific